Synthego raises $200 million to accelerate the field of CRISPR-based medicines from early-phase research to the clinic
Declaration is proud to support Synthego Corporation advance its cutting-edge genome engineering platform, which accelerates the field of CRISPR-based innovation from early-phase research through the clinic.